US Patent No: 5,208,020

Number of patents in Portfolio can not be more than 2000

Cytotoxic agents comprising maytansinoids and their therapeutic use

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA89

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 30 570
Chari, Ravi J Boston, MA 2 167
Goldmacher, Victor S Newton Center, MA 4 190
Lambert, John M Cambridge, MA 15 396

Cited Art

Patent Info (Count) # Cites Year
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (12)
4,248,870 Maytansinoids and use 24 1979
4,260,608 Maytansinoids, pharmaceutical compositions thereof and methods of use thereof 23 1979
4,263,294 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 2 1979
4,294,757 20-O-Acylmaytansinoids 27 1980
4,307,016 Demethyl maytansinoids 28 1980
4,308,268 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 23 1980
4,308,269 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 23 1980
4,264,596 Maytansinoids, pharmaceutical compositions thereof and method of use thereof 4 1980
4,309,428 Maytansinoids 23 1980
4,362,663 Maytansinoid compound 26 1980
4,364,866 Maytansinoids 27 1980
4,424,219 9-Thiomaytansinoids and their pharmaceutical compositions and use 29 1982
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (2)
4,313,946 Chemotherapeutically active maytansinoids from Trewia nudiflora 28 1981
4,418,064 Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone 14 1982
 
REICHERT-JUNG OPTISCHE WERKE A.G. (1)
4,256,246 Device for breaking a glass plate so as to obtain a sharp edge 16 1979

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
IMMUNOGEN, INC. (28)
6,333,410 Process for the preparation and purification of thiol-containing maytansinoids 44 2000
7,303,749 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 6 2000
7,097,840 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates 39 2001
6,441,163 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents 47 2001
6,716,821 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same 20 2001
7,368,565 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents 1 2002
RE39151 Process for the preparation and purification of thiol-containing maytansinoids 0 2003
7,374,762 Drug conjugate composition 2 2004
8,088,387 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates 0 2004
7,432,088 Methods for the production of ansamitocins 0 2005
7,601,354 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 0 2006
7,811,572 Process for preparing purified drug conjugates 0 2006
7,514,080 Drug conjugate composition 3 2006
7,501,120 Drug conjugate composition 2 2006
7,494,649 Drug conjugate composition 2 2006
8,435,528 Cytotoxic agents comprising new maytansinoids 0 2007
7,851,432 Cytotoxic agents comprising new maytansinoids 1 2007
8,198,417 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
8,163,888 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
7,989,598 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 0 2007
8,337,856 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates 0 2007
8,093,358 Methods of treatment using anti-erbb antibody-maytansinoid conjugates 0 2007
8,137,669 Elimination of heterogeneous or mixed cell population in tumors 0 2008
8,012,978 Prodrugs of CC-A1065 analogs 0 2008
8,012,485 Drug conjugate composition 1 2009
8,383,122 Process for preparing purified drug conjugates 0 2010
8,388,960 Elimination of heterogeneous or mixed cell population in tumors 0 2011
RE43899 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents 0 2012
 
GENENTECH, INC. (19)
6,824,780 Anti-tumor antibody compositions and methods of use 42 2000
6,914,130 Compositions and methods for the diagnosis and treatment of tumor 5 2001
7,803,915 Antibody compositions for the diagnosis and treatment of tumor 0 2004
7,435,416 Anti-tumor antibody compositions and methods of use 1 2004
7,527,791 Humanized anti-TGF-beta antibodies 0 2005
7,528,236 Humanized anti-beta7 antagonists and uses therefor 1 2005
7,888,478 Compositions and methods for the treatment of tumor of hematopoietic origin 2 2005
7,858,330 Compositions and methods for the treatment of tumor of hematopoietic origin 2 2006
7,575,748 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates 8 2006
7,754,441 Compositions and methods for the treatment of tumor of hematopoietic origin 0 2006
7,687,605 Humanized anti-beta7 antagonists and uses therefor 1 2007
7,951,546 Compositions and methods for the diagnosis and treatment of tumor 0 2008
8,088,378 Anti-CD79B antibodies and immunoconjugates and methods of use 0 2008
8,142,784 Antibody-drug conjugates and methods 2 2008
8,124,082 Humanized anti-beta7 antagonists and uses therefor 0 2009
8,012,482 Humanized anti-TGF-beta antibodies 0 2009
8,226,945 Antibodies and immunoconjugates and uses therefor 1 2010
8,388,973 Compositions and methods for the treatment of tumor of hematopoietic origin 0 2010
8,394,607 Anti-CD22 antibodies and immunoconjugates and methods of use 0 2012
 
XENCOR, INC. (9)
8,093,357 Optimized Fc variants and methods for their generation 2 2006
7,557,190 Optimized proteins that target Ep-CAM 1 2006
8,388,955 Fc variants 0 2007
8,101,720 Immunoglobulin insertions, deletions and substitutions 3 2008
8,063,187 Methods and compositions for inhibiting CD32B expressing cells 1 2008
8,367,805 Fc variants with altered binding to FcRn 0 2008
8,338,574 FC variants with altered binding to FCRN 0 2010
8,324,351 Fc variants with altered binding to FcRn 0 2010
8,318,907 Fc variants with altered binding to FcRn 0 2010
 
BIOGEN IDEC MA INC. (8)
7,531,174 Cripto blocking antibodies and uses thereof 4 2003
7,700,097 Purification and preferential synthesis of binding molecules 0 2004
7,582,299 Cripto-specific antibodies 0 2004
7,674,462 Cripto blocking antibodies and uses thereof 0 2007
8,021,661 Cripto binding molecules 0 2007
8,084,026 Multispecific binding molecules comprising connecting peptides 0 2007
8,003,763 Cripto blocking antibodies and uses thereof 0 2008
7,888,052 Cripto blocking antibodies and uses thereof 0 2009
 
IMMUNEX CORPORATION (8)
6,168,783 Antagonists of interleukin-15 5 1998
6,165,466 Antagonists of interleukin-15 9 1998
6,013,480 Antagonists of interleukin-15 6 1998
6,177,079 Antagonists of interleukin-15 6 1998
7,008,624 Antagonists of interleukin-15 1 2000
6,667,039 CD30 ligand 0 2000
7,235,240 Antagonists of interleukin-15 1 2005
7,763,434 Antagonists of interleukin-15 0 2007
 
THERACLONE SCIENCES, INC. (4)
8,057,796 Compositions and methods for the therapy and diagnosis of influenza 0 2008
7,982,012 Compositions and methods for the therapy and diagnosis of cytomegalovirus 0 2009
8,114,402 Compositions and methods for the therapy and diagnosis of influenza 0 2010
8,268,309 Compositions and methods for the therapy and diagnosis of cytomegalovirus 0 2011
 
ALCHEMIA ONCOLOGY PTY LIMITED (2)
8,287,894 Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease 0 2005
8,388,993 Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer 0 2006
 
BRISTOL-MYERS SQUIBB COMPANY (2)
6,214,345 Lysosomal enzyme-cleavable antitumor drug conjugates 61 1993
5,824,805 Branched hydrazone linkers 6 1996
 
GLAXOSMITHKLINE LLC (2)
6,570,024 Process and intermediates 0 2001
6,884,874 Process and intermediates 0 2003
 
SANOFI (2)
8,163,736 Cytotoxic agents comprising new tomaymycin derivatives 0 2008
8,404,678 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 0 2010
 
ARCHEMIX CORP. (1)
7,767,803 Stabilized aptamers to PSMA and their use as prostate cancer therapeutics 0 2006
 
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (1)
8,258,100 Ligand/lytic peptide methods of use 0 2009
 
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (1)
7,361,347 Cytotoxic CD44 antibody immunoconjugates 0 2005
 
COMPUGEN LTD. (1)
7,745,391 Human thrombospondin polypeptide 8 2006
 
F. HOFFMANN-LA ROCHE AG (1)
8,410,250 Anti-FGFR3 antibodies and methods using same 0 2010
 
HOFFMANN-LA ROCHE INC. (1)
7,981,418 Predicting response to a HER inhibitor 3 2008
 
IMMUNER CORP. (1)
7,067,132 Antagonists of interleukin-15 1 2002
 
JAKWANG CO., LTD. (1)
7,511,023 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof 2 2002
 
JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. (1)
6,368,598 Drug complex for treatment of metastatic prostate cancer 11 1998
 
MS TECHNOLOGIES, LLC (1)
7,749,504 Anti-TAT188 antibodies 0 2007
 
PLANTIBODIES CORPORATION (1)
6,251,392 Epithelial cell targeting agent 10 1997
 
SELVAMEDICA, LLC (1)
7,879,369 Mart. extract and methods of extracting and using such extract 0 2008
 
SMITHKLINE BEECHAM P.L.C. (1)
6,573,074 Methods for ansamitocin production 7 2001
 
SYNTHON BIOPHARMACEUTICALS B.V. (1)
6,440,419 Epithelial cell targeting agent 12 1998